Right Brain Bio is Repurposing Anticancer Medication RB-190 for Parkinson’s

Right Brain Bio is repurposing RB-190, an approved therapy, as a potential treatment for Parkinson’s disease and is preparing to seek approval from the U.S. Food and Drug Administration (FDA) for a Phase 2 clinical trial. The company plans to test whether RB-190 can slow disease progression and has partnered with Suven Pharmaceuticals to handle its manufacturing. RB-190 is a reformulated version of metyrosine, an FDA-approved drug used for a rare adrenal gland tumor. Research led by Right Brain Bio’s founder, Jonathan Sackner-Bernstein, suggests that excessive free dopamine in nerve cells may contribute to Parkinson’s progression. RB-190 works by reducing dopamine levels, which could help protect nerve cells and ease symptoms. Preclinical studies in lab-grown cells and animal models suggest metyrosine may prevent nerve cell death. Repurposing an existing drug could expedite clinical testing and lower the risk of unexpected side effects. The FDA has reviewed the science behind RB-190 and has agreed that the company can submit an investigational new drug (IND) application, which, if approved, would allow Phase 2 trials to proceed. Suven Pharmaceuticals, known for its FDA-audited facilities and global collaborations, will manufacture RB-190. Company executives from both Right Brain Bio and Suven emphasize their commitment to high-quality production and regulatory compliance as they advance RB-190 toward clinical trials.